Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

Kathy Miller, J. Picus, C. Blanke, W. John, J. Clark, L. N. Shulman, D. Thornton, E. Rowinsky, Patrick Loehrer

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Purpose: To determine the safety and activity of LY231514 (ALIMTA(TM), MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced pancreatic cancer. Patients and methods: Patients with unresectable or metastatic pancreatic cancer received LY231514 600 mg/m2 as a 10-minute infusion every three weeks. Results: Forty-two patients were enrolled in this phase II trial. The median age was 60.3 (range 37-77) years; 79% had metastatic disease. Neutropenia was common (40% of patients ≥ grade 3) but infectious complications were rare. Significant anemia or thrombocytopenia occurred in < 20% of patients. Non- hematologic toxicities included grade 2 or 3 skin reaction which was ameliorated by dexamethasone. Elevations of bilirubin or transaminases were infrequent (< 25% of patients) and did not require dose reductions or treatment delays. Thirty-five patients received two cycles of therapy and were evaluable for response. One complete (duration 16.2 months) and one partial (duration 6.9 months) were observed resulting in an objective response rate of 5.7% for evaluable patients. In addition, 17 patients (40%) had stable disease that lasted ≥6 months in 5 patients. The median survival was 6.5 months, with 28% of patients alive at one year. Conclusions: LY231514 is a well-tolerated agent with minimal objective antitumor activity in pancreatic cancer. The median and one year survival times, which may be important indicators in phase II trials of new agents, are of interest. Combination trials of LY231514 in pancreatic cancer are planned.

Original languageEnglish
Pages (from-to)101-103
Number of pages3
JournalAnnals of Oncology
Volume11
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Pemetrexed
Folic Acid Antagonists
Pancreatic Neoplasms
Survival

Keywords

  • Antifolate
  • Chemotherapy
  • Pancreatic cancer
  • Thymidylate synthase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. / Miller, Kathy; Picus, J.; Blanke, C.; John, W.; Clark, J.; Shulman, L. N.; Thornton, D.; Rowinsky, E.; Loehrer, Patrick.

In: Annals of Oncology, Vol. 11, No. 1, 2000, p. 101-103.

Research output: Contribution to journalArticle

Miller, Kathy ; Picus, J. ; Blanke, C. ; John, W. ; Clark, J. ; Shulman, L. N. ; Thornton, D. ; Rowinsky, E. ; Loehrer, Patrick. / Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. In: Annals of Oncology. 2000 ; Vol. 11, No. 1. pp. 101-103.
@article{f2514ecb9f314333a599359249acc6b3,
title = "Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer",
abstract = "Purpose: To determine the safety and activity of LY231514 (ALIMTA(TM), MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced pancreatic cancer. Patients and methods: Patients with unresectable or metastatic pancreatic cancer received LY231514 600 mg/m2 as a 10-minute infusion every three weeks. Results: Forty-two patients were enrolled in this phase II trial. The median age was 60.3 (range 37-77) years; 79{\%} had metastatic disease. Neutropenia was common (40{\%} of patients ≥ grade 3) but infectious complications were rare. Significant anemia or thrombocytopenia occurred in < 20{\%} of patients. Non- hematologic toxicities included grade 2 or 3 skin reaction which was ameliorated by dexamethasone. Elevations of bilirubin or transaminases were infrequent (< 25{\%} of patients) and did not require dose reductions or treatment delays. Thirty-five patients received two cycles of therapy and were evaluable for response. One complete (duration 16.2 months) and one partial (duration 6.9 months) were observed resulting in an objective response rate of 5.7{\%} for evaluable patients. In addition, 17 patients (40{\%}) had stable disease that lasted ≥6 months in 5 patients. The median survival was 6.5 months, with 28{\%} of patients alive at one year. Conclusions: LY231514 is a well-tolerated agent with minimal objective antitumor activity in pancreatic cancer. The median and one year survival times, which may be important indicators in phase II trials of new agents, are of interest. Combination trials of LY231514 in pancreatic cancer are planned.",
keywords = "Antifolate, Chemotherapy, Pancreatic cancer, Thymidylate synthase inhibitor",
author = "Kathy Miller and J. Picus and C. Blanke and W. John and J. Clark and Shulman, {L. N.} and D. Thornton and E. Rowinsky and Patrick Loehrer",
year = "2000",
doi = "10.1023/A:1008305205159",
language = "English",
volume = "11",
pages = "101--103",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

AU - Miller, Kathy

AU - Picus, J.

AU - Blanke, C.

AU - John, W.

AU - Clark, J.

AU - Shulman, L. N.

AU - Thornton, D.

AU - Rowinsky, E.

AU - Loehrer, Patrick

PY - 2000

Y1 - 2000

N2 - Purpose: To determine the safety and activity of LY231514 (ALIMTA(TM), MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced pancreatic cancer. Patients and methods: Patients with unresectable or metastatic pancreatic cancer received LY231514 600 mg/m2 as a 10-minute infusion every three weeks. Results: Forty-two patients were enrolled in this phase II trial. The median age was 60.3 (range 37-77) years; 79% had metastatic disease. Neutropenia was common (40% of patients ≥ grade 3) but infectious complications were rare. Significant anemia or thrombocytopenia occurred in < 20% of patients. Non- hematologic toxicities included grade 2 or 3 skin reaction which was ameliorated by dexamethasone. Elevations of bilirubin or transaminases were infrequent (< 25% of patients) and did not require dose reductions or treatment delays. Thirty-five patients received two cycles of therapy and were evaluable for response. One complete (duration 16.2 months) and one partial (duration 6.9 months) were observed resulting in an objective response rate of 5.7% for evaluable patients. In addition, 17 patients (40%) had stable disease that lasted ≥6 months in 5 patients. The median survival was 6.5 months, with 28% of patients alive at one year. Conclusions: LY231514 is a well-tolerated agent with minimal objective antitumor activity in pancreatic cancer. The median and one year survival times, which may be important indicators in phase II trials of new agents, are of interest. Combination trials of LY231514 in pancreatic cancer are planned.

AB - Purpose: To determine the safety and activity of LY231514 (ALIMTA(TM), MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced pancreatic cancer. Patients and methods: Patients with unresectable or metastatic pancreatic cancer received LY231514 600 mg/m2 as a 10-minute infusion every three weeks. Results: Forty-two patients were enrolled in this phase II trial. The median age was 60.3 (range 37-77) years; 79% had metastatic disease. Neutropenia was common (40% of patients ≥ grade 3) but infectious complications were rare. Significant anemia or thrombocytopenia occurred in < 20% of patients. Non- hematologic toxicities included grade 2 or 3 skin reaction which was ameliorated by dexamethasone. Elevations of bilirubin or transaminases were infrequent (< 25% of patients) and did not require dose reductions or treatment delays. Thirty-five patients received two cycles of therapy and were evaluable for response. One complete (duration 16.2 months) and one partial (duration 6.9 months) were observed resulting in an objective response rate of 5.7% for evaluable patients. In addition, 17 patients (40%) had stable disease that lasted ≥6 months in 5 patients. The median survival was 6.5 months, with 28% of patients alive at one year. Conclusions: LY231514 is a well-tolerated agent with minimal objective antitumor activity in pancreatic cancer. The median and one year survival times, which may be important indicators in phase II trials of new agents, are of interest. Combination trials of LY231514 in pancreatic cancer are planned.

KW - Antifolate

KW - Chemotherapy

KW - Pancreatic cancer

KW - Thymidylate synthase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0033981350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033981350&partnerID=8YFLogxK

U2 - 10.1023/A:1008305205159

DO - 10.1023/A:1008305205159

M3 - Article

VL - 11

SP - 101

EP - 103

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -